Mind Medicine (MindMed)’s (MNMD) Overweight Rating Reaffirmed at Cantor Fitzgerald

Cantor Fitzgerald reissued their overweight rating on shares of Mind Medicine (MindMed) (NASDAQ:MNMDFree Report) in a research report released on Friday morning, Benzinga reports.

Several other research firms have also issued reports on MNMD. HC Wainwright reissued a buy rating and set a $35.00 target price on shares of Mind Medicine (MindMed) in a report on Friday, May 24th. SVB Leerink started coverage on Mind Medicine (MindMed) in a research note on Monday, April 15th. They issued an outperform rating and a $20.00 price objective on the stock. Robert W. Baird started coverage on Mind Medicine (MindMed) in a research note on Tuesday, May 28th. They issued an outperform rating and a $27.00 price objective on the stock. Baird R W raised Mind Medicine (MindMed) to a strong-buy rating in a research note on Wednesday, May 29th. Finally, Oppenheimer reaffirmed an outperform rating and issued a $20.00 price objective (down from $29.00) on shares of Mind Medicine (MindMed) in a research note on Monday, May 13th. Eight equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of Buy and an average target price of $20.00.

Check Out Our Latest Analysis on Mind Medicine (MindMed)

Mind Medicine (MindMed) Stock Performance

MNMD opened at $7.38 on Friday. The firm has a market cap of $518.58 million, a P/E ratio of -2.51 and a beta of 2.64. Mind Medicine has a 52-week low of $2.41 and a 52-week high of $12.22. The company has a debt-to-equity ratio of 0.07, a quick ratio of 3.91 and a current ratio of 3.91. The business’s fifty day moving average is $8.46 and its 200-day moving average is $6.78.

Mind Medicine (MindMed) (NASDAQ:MNMDGet Free Report) last released its earnings results on Wednesday, May 8th. The company reported ($0.60) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.66) by $0.06. Sell-side analysts expect that Mind Medicine will post -1.36 EPS for the current fiscal year.

Hedge Funds Weigh In On Mind Medicine (MindMed)

Large investors have recently bought and sold shares of the company. SageView Advisory Group LLC bought a new position in Mind Medicine (MindMed) in the first quarter valued at about $25,000. Regal Investment Advisors LLC bought a new position in Mind Medicine (MindMed) in the third quarter valued at about $46,000. Bailard Inc. bought a new position in Mind Medicine (MindMed) in the fourth quarter valued at about $63,000. Sequoia Financial Advisors LLC bought a new position in Mind Medicine (MindMed) in the first quarter valued at about $168,000. Finally, Mitchell Mcleod Pugh & Williams Inc. bought a new position in Mind Medicine (MindMed) in the fourth quarter valued at about $73,000. 27.91% of the stock is currently owned by institutional investors.

Mind Medicine (MindMed) Company Profile

(Get Free Report)

Mind Medicine (MindMed) Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company's lead product candidates include MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase I clinical trials for the treatment of core symptoms of autism spectrum disorder.

Featured Stories

Analyst Recommendations for Mind Medicine (MindMed) (NASDAQ:MNMD)

Receive News & Ratings for Mind Medicine (MindMed) Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mind Medicine (MindMed) and related companies with MarketBeat.com's FREE daily email newsletter.